Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021

Rhea-AI Summary

Avid Bioservices, Inc. (NASDAQ:CDMO) will release its first quarter fiscal year 2022 financial results on September 8, 2021, after market close. A conference call and webcast will take place at 1:30 PM PT for management to discuss these results and recent developments. The event aims to provide insights into the company's performance and ongoing initiatives. Investors can access the live audio through the company’s investor relations page.

Positive

• Upcoming financial results may indicate growth or improved metrics for Avid Bioservices.
• The conference call offers an opportunity for investors to gain insights on corporate developments.

Negative

• None.

TUSTIN, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2022 on September 8, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

FAQ

When will Avid Bioservices report its first quarter financial results for fiscal year 2022?

Avid Bioservices will report its financial results on September 8, 2021, after market close.

What time is the Avid Bioservices conference call scheduled for?

The conference call is scheduled for 1:30 PM Pacific Time (4:30 PM Eastern Time) on September 8, 2021.

How can I listen to the Avid Bioservices conference call?

You can listen to the conference call by dialing (877) 312-5443 or (253) 237-1126.

Where can I find the archived webcast of the Avid Bioservices financial results?

The archived webcast will be available on Avid Bioservices' investor relations page.